Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Decompensated Heart Failure

In brief

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Key facts

Study ID

NCT00839007

Run by

Nile Therapeutics

People needed

77

Starts

2009-06-01

Expected to finish

2010-07-01

Last updated by the study team

2010-09-17

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Torrance, California, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami Beach, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Iowa City, Iowa, United States
• Study site — Detroit, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — The Bronx, New York, United States
• Study site — Houston, Texas, United States
• Study site — Berlin, Germany
• Study site — Berlin, Germany
• Study site — Dortmund, Germany
• Study site — Neuss, Germany
• Study site — Würzberg, Germany
• Study site — Ashkelon, Israel
• Study site — Haifa, Israel
• Study site — Nazareth, Israel
• Study site — Petah Tikva, Israel
• Study site — Safed, Israel
• Study site — Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.